Genmab — April 2018
-
Pudsigt, i pressemeddelelsen skriver Genmab at det er et fase 2/3 studie. På ct står det som fase 1?? https://clinicaltrials.gov/ct2/show/NCT03357952?term=mmy2036&rank=1 Men det er måske det, de mener med et multi-fase-studie. Og at effekt-delen i part 3 er nok til at file på? Der er jo pænt mange pts med.
-
Holdt foredrag i Svinningehallen her til aften. Genmab er stadig en folkeaktie.
-
Lidt fra Firstword: Final thoughts
Of course, one of the most high-profile reckonings for an ADC- and the PBD dimers used by ADC Therapeutics- will come from Stemcentrx and AbbVie's highly anticipated TRITON study of Rova-T. Unfortunately, AbbVie has already signalled that the outcome with be poor for the small-cell lung cancer candidate (SCLC);
-
last month it disclosed some mixed data and indicated it would not be pursuing accelerated approval for the compound. That said, companies like ADC Therapeutics can be confident that as long as the readout isn't dripping with safety concerns, their platform should still have legs
-
God morgen.
-
God morgen
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind